Clinical Trials Browser

Interventional × Carcinoma, Hepatocellular × Immunoglobulin G × Clear all

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04721132 2026-03-05

Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03942328 2026-02-24

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Phase 1/2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT07174570 2026-01-28

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04430452 2025-12-08

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04605731 2025-09-10

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

Phase 1 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05194293 2025-09-04

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT01010126 2019-01-25

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Phase 2 Completed

252 enrolled 20 charts

GastrointestinalGynecologic

Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Somatostatinoma

NCT01804829 2017-03-15

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

Phase 3 Completed

Gastrointestinal

Hepatitis, Viral, Human, Hepatitis C, Carcinoma, Hepatocellular, Liver Cirrhosis, Virus Diseases